Physician profile
Alfredo Castillo
NPI 1558357970
$6,887.88
in general payments reported to CMS, 2019-2025
28 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $652 · 2021: $739 · 2022: $685 · 2023: $957 · 2024: $2,060 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,543 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,543.13 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,542.50 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $969.32 | 2020-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $513.45 | 2019-2025 | |
| Lilly USA, LLC | $486.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $441.06 | 2020-2022 | |
| Amgen INC. | $436.08 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.12 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $212.89 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $137.52 | 2020 | |
| Glaxosmithkline, LLC. | $125.89 | 2020-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $114.40 | 2024 | Voquezna |
| Abbvie INC. | $91.72 | 2021-2023 | Linzess, Creon |
| Novartis Pharmaceuticals Corporation | $87.93 | 2019 | |
| Cardiovascular Systems INC. | $76.09 | 2022 | |
| Xeris Pharmaceuticals, INC. | $63.79 | 2024-2025 | Gvoke Hypopen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $61.02 | 2020-2025 | Nexletol |
| Pfizer INC. | $57.05 | 2023-2025 | |
| Astellas Pharma US INC | $46.92 | 2024 | Veozah |
| Biotronik Nro, INC. | $23.98 | 2025 | Prospera |
| Ars Pharmaceuticals Operations, INC. | $23.06 | 2025 | Neffy |
| Vertex Pharmaceuticals Incorporated | $22.80 | 2025 | |
| Corcept Therapeutics | $20.17 | 2025 | Korlym |
| Shield Therapeutics INC | $19.94 | 2024 | |
| Radius Health, INC. | $19.61 | 2023 | |
| Merck Sharp & Dohme LLC | $19.53 | 2025 | Capvaxive, Gardasil 9 |
| Sanofi-Aventis U.S. LLC | $16.35 | 2019 | |
| Ferring Pharmaceuticals INC. | $15.65 | 2024 | Euflexxa |
| Kowa Pharmaceuticals America, INC. | $14.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Castillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.